Journal Watch · Nature Immunology · 2026

TSLP promotes GATA3-expressing effector regulatory T cells via DC2 derived from transitional DCs.

Our data demonstrated that TSLP acts on transitional dendritic cell-derived DC2 to promote GATA3<sup>+</sup> eT<sub>reg</sub> cells, thus uncovering a previously unrecognized tolerogenic axis in promoting immunosuppression, which is likely conserved in humans, across contexts of inflammation and cancer.

Guivarch M, Meyer P, Braud A et al.Nature Immunology3 min readPharma relevance 30/100

DOI: 10.1038/s41590-025-02400-7PMID: 41593243Study type: preclinical (animal / model) study

TL;DR

Our data demonstrated that TSLP acts on transitional dendritic cell-derived DC2 to promote GATA3<sup>+</sup> eT<sub>reg</sub> cells, thus uncovering a previously unrecognized tolerogenic axis in promoting immunosuppression, which is likely conserved in humans, across contexts of inflammation and cancer.

Key findings

  • By conducting transcriptomic identity, lineage-traced ontogeny, surface marker expression and functional studies, we identified and characterized this DC population.
  • Our data demonstrated that TSLP acts on transitional dendritic cell-derived DC2 to promote GATA3<sup>+</sup> eT<sub>reg</sub> cells, thus uncovering a previously unrecognized tolerogenic axis in promoting immunosuppression, which is likely conserved in humans, across contexts of inflammation and cancer.

What they did

In this study, using an experimental mouse model with induced TSLP expression by epidermal keratinocytes combined with genetic tools, we find that TSLP drives GATA3<sup>+</sup> eT<sub>reg</sub> cells through a specific migratory DC population where the co-stimulatory molecule OX40L is required.

Full abstract (original)

Background: Thymic stromal lymphopoietin (TSLP), initially described as a driver of type 2 helper T cell responses, can also act on dendritic cells (DCs) to promote the generation and accumulation of GATA3-expressing effector regulatory T (eT<sub>reg</sub>) cells in the context of cutaneous melanoma.

What they did: In this study, using an experimental mouse model with induced TSLP expression by epidermal keratinocytes combined with genetic tools, we find that TSLP drives GATA3<sup>+</sup> eT<sub>reg</sub> cells through a specific migratory DC population where the co-stimulatory molecule OX40L is required.

Results & conclusions: By conducting transcriptomic identity, lineage-traced ontogeny, surface marker expression and functional studies, we identified and characterized this DC population. Our data demonstrated that TSLP acts on transitional dendritic cell-derived DC2 to promote GATA3<sup>+</sup> eT<sub>reg</sub> cells, thus uncovering a previously unrecognized tolerogenic axis in promoting immunosuppression, which is likely conserved in humans, across contexts of inflammation and cancer.

Abstract © the authors / Nature Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1038/s41590-025-02400-7 · PubMed 41593243.

Why it matters for pharma & biotech

  • Relevant to Immunology teams tracking Nature Immunology for new targets, mechanisms and biomarkers.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Nature Immunology study find?

Our data demonstrated that TSLP acts on transitional dendritic cell-derived DC2 to promote GATA3<sup>+</sup> eT<sub>reg</sub> cells, thus uncovering a previously unrecognized tolerogenic axis in promoting immunosuppression, which is likely conserved in humans, across contexts of inflammation and cancer.

What type of study is this?

It is a preclinical (animal / model) study, published in Nature Immunology in 2026. In this study, using an experimental mouse model with induced TSLP expression by epidermal keratinocytes combined with genetic tools, we find that TSLP drives GATA3<sup>+</sup> eT<sub>reg</sub> cells through a specific migratory DC population where the co-stimulatory molecule OX40L is required.

Where can I read the original paper?

The original is at the publisher via DOI 10.1038/s41590-025-02400-7. PubMed ID: 41593243. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Guivarch M, Meyer P, Braud A et al.. TSLP promotes GATA3-expressing effector regulatory T cells via DC2 derived from transitional DCs.. Nature Immunology (2026). DOI: 10.1038/s41590-025-02400-7.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/tslp-promotes-gata3-expressing-effector-regulatory-t-cells-via-dc2-deriv-024007/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides